Mark Neumann - 15 Oct 2021 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role: EVP, Chief Commercial Officer
Signature: /s/ Lawrence J. Hineline, Attorney-in-fact
Issuer symbol: ITCI
Transactions as of: 15 Oct 2021
Net transactions value: -$549,551
Form type: 4
Filing time: 19 Oct 2021, 16:26:02 UTC
Next filing: 11 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ITCI	Common Stock	Options Exercise		+13,448	+30%		58,787	15 Oct 2021	Direct	F1
transaction	ITCI	Common Stock	Sale	$278,066	-6,702	-11%	$41.49	52,085	18 Oct 2021	Direct	F2, F3
transaction	ITCI	Common Stock	Sale	$174,822	-4,288	-8.2%	$40.77	47,797	18 Oct 2021	Direct	F2, F4
transaction	ITCI	Common Stock	Sale	$77,224	-1,958	-4.1%	$39.44	45,839	18 Oct 2021	Direct	F2, F5
transaction	ITCI	Common Stock	Sale	$19,440	-500	-1.1%	$38.88	45,339	18 Oct 2021	Direct	F2, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ITCI	Restricted Stock Units	Options Exercise	$0	-13,448	-100%	$0.000000^*	0	15 Oct 2021	Common Stock	13,448		Direct	F7, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. A substantial portion of the proceeds from these sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.04 to $42.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.34 to $41.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.02 to $40.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.60 to $39.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F7	Each restricted stock unit represents a contingent right to receive one share of common stock.
F8	The restricted stock units vest as to one third of the shares on October 15, 2019, one third of the shares on October 15, 2020 and one third of the shares on October 15, 2021.